Últimos Artículos de Lancet Diabetes & Endocrinology
- [Editorial] Diabetes in a warming world
- [Correspondence] Time for personalised incretin titration
- [Articles] Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial
- [Comment] Safety and tolerability of orforglipron in Japanese people with type 2 diabetes
- [In Focus] Toxic chemicals: the fight for planetary health
- [Articles] Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
- [Comment] Type 2 diabetes management: weekly combination therapy comes of age?
- [Correspondence] Do weight loss and weight cycling present a clinically meaningful risk in older patients?
- [Articles] Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial
- [Comment] Redrawing the lines for the management of obesity in Asia
- [Articles] Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis
- [Comment] Less can be more: the 2026 Endocrine Society Guideline for precision care in central precocious puberty
- [Review] Type 1 diabetes in older populations
- [Editorial] Soaring GLP-1 receptor agonist use
- [Editorial] Energy drink ban: putting children's health first
- [Viewpoint] Goal-directed osteoporosis treatment: are bone mineral density targets valid?
- [Review] Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement
- [Articles] Temporal changes in cortisol secretion and their association with long-term outcomes in benign adrenal incidentalomas: a retrospective cohort study
- [Articles] Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial
- [Comment] Insulin and health systems in global low-resource settings